Effect of the heme/heme oxygenase pathway on the relationship between salt consumption and blood pressure

Journal of Hypertension

Volumn 16, Issue 12 SUPPL., 1998, Pages 1965-1969

  Dos Santos, Elisabete A ^a   Yamaguishi, Gilberto A ^a   Heimann, Joel C ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Nephrology Division   (Brazil)

Author keywords

Blood pressure; Carbon monoxide; Heme oxygenase; Salt; Sodium; Sodium chloride

Indexed keywords

BILIVERDIN; CARBON MONOXIDE; FERRIC ION; HEME DERIVATIVE; HEME OXYGENASE; HEME OXYGENASE INHIBITOR; PROTOPORPHYRIN ZINC; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; BLOOD PRESSURE; CONFERENCE PAPER; DEGRADATION; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SALT INTAKE;

EID: 0032437932     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199816121-00017     Document Type: Conference Paper

References (25)

1. Sjörstrand J. Endogenous formation of carbon monoxide in man under normal and pathological conditions. Scand J Clin Lab Invest 1949; 1: 201.
2. Abraham NG, Lin JH-C, Schartzman ML, Levere RD, Shibahara S. The physiological significance of heme oxygenase. Int J Biochem 1988; 20:543-558.
3. Maines MD. Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J 1988; 2:2557-2568.
4. Marks GS, Brien JF, Nakatsu K, McLaughtin BE. Does carbon monoxide have a physiological function? Trends Pharmacol Sci 1991; 12: 185-188.
5. Maines MD. Heme oxygenase and degrading systems. In Heme Oxygenase: Clinical Applications and Function. Edited by Maines MD. CRC Press; 1992: 63-108.
6. Vreman HJ, Lee OK, Stevenson DK. In vitro and in vivo characteristics of a heme oxygenase inhibitor. Am J Med Sci 1991; 302:335-341.
7. Schmidt HHHW. NO, CO, and HO endogenous soluble guanylyl cyclase-activating factors. FEBS Lett 1992; 307:102-107.
8. Stocker R, McDonagh AF, Glazer AN, Ames BN. Antioxidant activities of bile pigments: biliverdin and bilirubin. Methods Enzymol 1990; 186:301-311.
9. Mehlhorn RJ, Gomez J. Hydroxyl and alkoxyl radical production by oxidation products of metmyoglobin. Free Radical Res Commun 1993; 18: 29-41.
10. Vercellotti GM, Tolins JP. Endothelial activation and the kidneys: vasomediator modulation and antioxidant strategies. Am J Kidney Dis 1993; 21:331-343.
11. Ambard L. Beaujard E. Causes de l'hypertension arterielle. Arch Gen Med 1904; 1:520-533.
12. Law MR, Prost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? I - Analysis of observational data among populations. Br Med J 1991; 302:811-815.
13. Dichtchekenian V, Sequeira DMC, Andriollo A, Marcondes M, Heimann JC. Salt sensitivity in human essential hypertension: effect of renin-angiotensin and sympathetic nervous system blockade. Clin Exper Hypertens 1989; A11(suppl 1):379-387.
14. Dichtchekenian V, Gisiger S, Quental S, Santos SRCJ, Mardondes M, Heimann JC. Higher salt consumption, digoxin-like factor, and nifedipine response are associated with salt sensitivity in essential hypertension. Am J Hypertens 1992; 5:707-712.
15. Dahl LK, Knudsen KD, Heine MA, Leitl, GJ. Effects of chronic excess salt ingestion. Modification of experimental hypertension in the rat by variations in the diet. Circ Res 1968; 22:11-18.
16. Lima NKC, Lima FB, Santos EA, Okamoto MM, Matsushita DH, Hell NS, Heimann JC. Chronic sodium chloride overload increases blood pressure and improves glucose metabolism, without changing insulin sensitivity. Am J Hypertens 1997; 10:720-727.
17. Selye H, Hall CE, Rowley EM. Malignant hypertension produced by treatment with deoxycorticosterone acetate and sodium chloride. Can Med Assoc J 1943; 49:88-92.
18. Johnson RA, Lavesa M, Askari B, Abraham NG, Nasjletti A. A heme oxygenase product, presumably carbon monoxide, mediates a vasodepressor function in rats. Hypertension 1995; 25:166-169.
19. Overlack A, Stumpe KO, Kuhnert M, Heck I. Altered blood pressure and renin responses to converting enzyme inhibition after aprotinin-induced kallikrein-kinin system blockade. Clin Sci 1980; 59:129S-132S.
20. Gavras H, Brunner HR, Turini GA, Kershaw GR, Tifft CP, Cuttelod S, et al. Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ14225 in man. N Engl J Med 1978; 298:991-995.
21. Maines MD. The heme oxygenase system: a regulator of second messenger gases. Ann Rev Pharmacol Toxicot 1997; 37:517-554.
22. Llesuy SF, Tomaro ML. Heme oxygenase and oxidative stress: evidences of involvement of billirubin as physiological protector against oxidative damage. Biochim Biophys Acta 1994; 1223:9-14.
23. Schacter B. Heme catabolism by heme oxygenase: physiology, regulation, and mechanism of action. Semin Hematol 1988; 25:349-369.
24. Seki T, Naruse M, Naruse K, Yoshimoto T, Tanabe A, Imaki T, et al. Interrelation between nitric oxide synthase and heme oxygenase in rat endothelial cells. Eur J Pharmacol 1997; 331:87-91.
25. Ignarro LJ, Ballot B, Wood KS. Regulation of soluble guanylate cyclase activity by porphyrins and metalloporphyrins. J Biol Chem 1984; 259:6201-6207.